ACC.22: APOLLO, magnitude and duration of Lp(a) lowering with SLN360 (Steven Nissen)

Steven Nissen summarises APOLLO, the placebo-controlled single-ascending-dose study of SLN360 (Silence Therapeutics, later named zerlasiran) in 32 adults with Lp(a) of 150 nmol/L or more: the 300 and 600 mg doses lowered Lp(a) by 96 and 98 percent at peak, with reductions of 71 to 81 percent still present at day 150. Published simultaneously in JAMA. Recorded at ACC.22, Washington.